An IPO So Nice REGENXBIO Will Try It Twice
This article was originally published in Scrip
REGENXBIO Inc. is hoping to build on the success of its IPO – and investor enthusiasm for gene therapy in general – by taking its liver disease-focused spinout, Dimension Therapeutics Inc., public as well.
You may also be interested in...
Partnered with AbbVie on a wet AMD gene therapy, Regenxbio is also advancing wholly owned candidates for Duchenne muscular dystrophy and MPS I and MPS II.
Lotilaner, the active ingredient in Tarsus’s Demodex blepharitis drug Xdemvy, showed significant ability to kill ticks in a small Phase IIa study. Analysts call the Lyme program a likely out-licensing opportunity for Tarsus.
Having acquired Xiidra from Novartis and getting US approval of Miebo in 2023, B+L’s two-product dry eye franchise delivered 66% year-over-year growth during Q4 2023.